1. Health technology

  2. •

    Biotechnology
POLYPEPTIDE GROUP AG

POLYPEPTIDE GROUP AG

54.42
USD
0.00
(0.00%)
1.15BMarket Cap
POLYPEPTIDE GROUP AG
OTC:PLYGF
(OTC Markets)

Recent

price

54.42

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CHF
6.78
7.33
8.06
9.25
8.5
9.15
9.65
11.06
- -
Revenue per Share
0.89
0.93
1.12
1.53
0.23
-1.45
-0.56
-0.6
- -
Basic EPS, GAAP
0.17
1.29
0.23
-0.66
-2.2
-0.57
0.07
-0.89
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.29
- -
- -
- -
- -
Dividend per Share
5.04
4.91
5.82
13.2
12.67
10.74
10.17
9.61
9.61
Book Value per Share
4.67
4.5
5.4
12.75
12.2
10.27
9.74
9.21
9.21
Tangible Book Value per Share
30
30
30
32
33
33
33
33
33
Basic Weighted Avg Shares
204
221
243
297
280
302
318
365
- -
Sales/Revenue/Turnover
15.31
16.48
19.76
22.43
4.45
-10.43
-1.77
2.22
- -
Operating Margin (%)
16
17
19
21
26
28
31
35
- -
Depreciation Expense
27
28
34
49
8
-48
-18
-20
- -
Net Income, GAAP
19.13
14.87
16.85
21.04
- -
- -
- -
- -
- -
Effective Tax Rate (%)
13.14
12.64
13.95
16.52
2.74
-15.84
-5.78
-5.4
- -
Profit Margin (%)
87
92
84
236
154
139
126
129
129
Working Capital
28
37
38
16
17
63
55
116
116
LT Debt
166
162
192
437
417
354
336
317
317
Total Equity
- -
14.44
17.4
14.79
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
14.87
17.03
14.92
- -
- -
- -
- -
- -
Return on Capital (%)
- -
17
19.14
15.59
1.8
-12.39
-5.33
-6.04
- -
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
34
5
5
LT Borrowings
37
74
102
LT Finance Leases
18
15
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
33
Market Capitalization
- -
- -
908

Working Capital

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
308
299
302
Cash, Cash Equivalents & STI
64
72
69
Accounts Receivable, Net
77
51
57
Inventories
137
147
144
Total Current Liabilities
183
184
174
Payables & Accruals
- -
- -
- -
ST Debt
34
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
19.41%
-5.51%
Free Cash Flow
- -
-346.71%
-1,379.92%
Net Income, GAAP
- -
-163.08%
7.24%
Sales/Revenue/Turnover
- -
8.88%
14.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
302
2024
- -
- -
- -
- -
318
2025
- -
- -
- -
- -
365

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1.45
2024
- -
- -
- -
- -
-0.56
2025
- -
- -
- -
- -
-0.6

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business